Apogee Therapeutics

eczema atopic dermatitis Black African American patient skin of color
Biotech

Apogee claims IL-13 antibody sets new eczema treatment standard

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main goal of a phase 2 trial.
James Waldron Jul 7, 2025 8:29am
parachute chutes and ladders

Sanofi finds new R&D head—Chutes & Ladders

Sep 1, 2023 9:30am
Wall Street stock exchange finance shares share price Nasdaq

Apogee, Sagimet overshoot IPO expectations as they reach Nasdaq

Jul 14, 2023 8:55am
water thaw

2 biotechs test icy IPO waters with $228M and $66M offerings

Jul 10, 2023 11:43am